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The ‘2-week wait’ scheme for referral of patients with cancer to secondary care coincided with the introduction of Department of
Health (DoH) Guidelines on referral of patients with suspected lung cancer. The aim of this study was to examine the impact of this
process on the urgent referral pathway for lung cancer. Medical records of all patients referred with suspected lung cancer were
reviewed for the year prior to introduction of the 2-week wait and DoH guidelines and for the subsequent 24 months. A total of
1044 patients were referred, of which 650 (62%) were found to have malignancy. In the first and second years of the 2-week wait
scheme, only 57 and 58% were referred via the scheme. Department of Health guidelines were followed in all but a small number.
Median wait time increased from 7 to 9 days. The proportion of all urgent referrals seen within 2 weeks fell from 84 to 71%. The
proportion of non-2-week wait urgent referrals being seen within 2 weeks was only 75.5% in the first year of the scheme and fell
further to 60.9% in the second year. The absolute number of referrals rose and the proportion having cancer fell from 78% before the
scheme to 46% in the second year. During this time, there was no change in stage at presentation. Symptoms were not helpful in
discriminating benign from malignant disease and haemoptysis was actually more common in the benign group. However, over 50%
of patients in the benign group were appropriate to be seen in secondary care. The 2-week wait scheme has so far failed to reduced
waiting times for lung cancer. The findings of this study suggest that this is partly due to continued usage of urgent referral routes
outside the 2-week wait scheme and secondly due to a large increase in referrals, probably generated by the introduction of the DoH
guidelines. Some adjustment to the guidelines may be appropriate to reflect more emphasis on the early performance of a chest
X-ray and the use of direct access to other imaging modalities such as CT. Patients referred outside the 2-week wait are
disadvantaged and thus practitioners would be wise to refer all their patients through the 2-week wait system.
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The Government white paper The New NHS – Modern, Dependable
(Department of Health National Standards, Local Action, 2004)
proposed that everyone with suspected cancer should be given the
opportunity to be seen by a specialist within 2 weeks of the date of
the GP referral. In order to introduce this ‘2-week wait’ principle to
lung cancer, the Department of Health (DoH) introduced national
guidelines for the urgent referral of suspected lung carcinoma in
April 2000. The intention was to simplify and streamline the
referral process from primary care to respiratory physicians, thus
expediting treatment by specialist multidisciplinary units (Depart-
ment of Health NHS Improvement Plan June, 2004).
Here, we report on the utilisation and impact of this process on
the urgent referral pathway for lung cancer.
MATERIALS AND METHODS
Medical records of all patients referred with suspected lung cancer
to Nottingham City Hospital in the 12 months prior to the
introduction of DoH guidelines (1st April 1999–31st March 2000)
and the subsequent 24 months (1st April 2000–31st March 2002)
were retrospectively audited by three observers (NRL, DRB, ILJ).
The reason for referral, referral route and times from GP referral to
first hospital visit, investigations, diagnosis and treatment were
recorded along with outcome data including surgical stage
histological diagnosis, management plan and treatment modality.
Statistical comparisons for these nonparametric data were made
using the Mann–Whitney U-test. Fisher’s exact test and w
2 tests
were used for comparisons of proportions.
RESULTS
Number of patients referred and referral route
A total of 1044 patients were referred to the respiratory physicians
with a suspected diagnosis of lung cancer during the 3-year audit
period. In all, 628 (60.2%) were male and the median age was 73
years (range 24–98 years). Malignancy was confirmed in 650
(62.3%), of which 578 (88.9%) were found to have a primary lung
tumour. Of these 465 (80.4%) were non-small-cell carcinoma, 86
(14.9%) small-cell carcinoma, 22 (3.8%) mesothelioma and five
(0.9%) were other tumours.
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patients were referred via the 2-week wait scheme (201/352) in
2000/2001 and 58% (236/404) in 2001/2002.
Adherence to DoH guidelines for referral
Only four patients (1% of referrals) in the first year after
introduction of the guidelines, and 16 patients (4% of referrals)
in the second year failed to meet the criteria for urgent referral
listed in the DoH guidelines.
Effect of introduction of 2-week wait and DoH guidelines
on waiting times
Table 2 shows the median waiting times to points on the patient
pathway. Introduction of the 2-week wait principle and the DoH
guidelines for urgent referral has resulted in patients waiting
longer for their first hospital visit (median of 7 vs 9 days) and
longer for treatment of lung cancer. Time to diagnosis initially
increased and then returned to preguideline values.
The proportion of patients who were seen within 2 weeks was
84% prior to the introduction of the ‘2-week wait’ scheme and 85%
in the year after introduction of the 2-week wait. The proportion
fell to 71% (Po0.0001; Mann–Whitney U-test) in the year 2001–
2002. Analysis of the median waiting time by referral route
demonstrated that all of those patients referred via the ‘2-week
wait’ scheme were seen within that time; however, as a result of the
increase in absolute urgent referral numbers, the percentage of
those referred by a conventional route who were seen within 2
weeks dropped significantly to 75.5% in 2000–2001 and further to
60.9% (Po0.0001) in 2001–2002.
Reasons for referral
The most common reasons for referral were cough, dyspnoea,
weight loss, haemoptysis and chest pain. Table 3 shows the
proportion of patients with each symptom by year, divided into
patients with and without cancer. There was no difference in the
pattern of symptoms after introduction of DoH guidelines. The
frequency of these symptoms was found to be high in both patients
with and without cancer. Chest pain, dyspnoea and weight loss
were all more common in patients with lung cancer (Po0.0001),
but were still present in a large enough proportion of patients
without cancer to mean they were not good discriminators.
Haemoptysis was significantly more common in benign diagnoses
(Po0.0001).
An abnormal chest X-ray suggestive of lung cancer was the most
common referral basis accounting for 87.2% over the 3-year
period. The finding of a mass was more common in cancer
(Po0.0001), but 30% of benign diagnoses also had a mass on chest
radiograph. Consolidation and interstitial shadowing were more
common in nonmalignant conditions (Po0.0001).
Table 1 Number of referrals of suspected lung cancer
1st April
1999–31st
March 2000,
n (%)
1st April
2000–31st
March 2001,
n (%)
1st April
2001–31st
March 2002,
n (%)
Total number of referrals 286 352 404
2-Week wait referral 2 (0.6) 201 (57) 236 (58)
Urgent referral 279 (97.5) 142 (40) 153 (38)
Other referral
a 5 (1.7) 9 (2.5) 17 (4.2)
aPatients who were found to have lung cancer but were not referred via a recognised
urgent route.
Table 2 Effect of introduction of 2-week wait and DoH guidelines on waiting times
Waiting time in days: median (range)
1999–2000 (Department
of Health National
Standards, Local Action,
2004)
2000–2001 (Department
of Health NHS
Improvement Plan June,
2004)
2001–2002
(National Institute
for Clinical
Excellence, 2005) P-value
Referral to first hospital visit 7 (0–124) 8 (0–101) 9 (0–98) 0.0009 for 1 vs 3
Referral to diagnosis 26 (0–228) 33 (2–307) 27 (0–300) o0.00001 for 1 vs 2; 0.0003 for 2 vs 3
First hospital visit to diagnosis 15 (0–219) 21 (0–294) 15 (0–300) o0.00001 for 1 vs 2 and 2 vs 3
Referral to treatment 37 (2–228) 41 (2–307) 42 (0–239) o0.04 1 vs 2o r3
DoH¼Department of Health.
Table 3 Predominant symptoms of patients with and without cancer
Year
April 99–March 2000 April 2000–March 2001 April 2001–March 2002
Cancer Benign Cancer Benign Cancer Benign
Absolute % Absolute % Absolute % Absolute % Absolute % Absolute %
Total 224 100.0 62 100.0 240 100.0 112 100.0 186 100.0 218 100.0
Cough 76 33.9 40 64.5 89 37.1 88 78.6 101 54.3 127 58.3
Dyspnoea 131 58.5 23 37.1 131 54.6 59 52.7 93 50.0 71 32.6
Weight loss 102 45.5 16 25.8 151 62.9 40 35.7 55 29.6 44 20.2
Haemoptysis 52 23.2 19 30.6 45 18.8 34 30.4 43 23.1 66 30.3
Chest pain 97 43.3 10 16.1 116 48.3 40 35.7 43 23.1 30 13.8
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Table 4 shows the final diagnosis in all referrals. The proportion of
urgent referrals subsequently found to have a malignancy
decreased from 78% (224/286) prior to the introduction of the
guidelines and the ‘2-week wait’ scheme, to 68% (240/352) of
patients in the first year (Po0.0001) and 46% (186/404) of patients
in the second year after their introduction (Po0.0001).
Stage of non-small-cell lung cancer
Table 5 shows the number of patients in each surgical stage, where
stage was recorded. In 1999–2000, 75% of patients were staged, in
2000–2001, 71% and in 2001–2002, 77%. There was no significant
change in stage (w
2, 2.52; P¼0.47)
Benign diagnoses
Table 6 shows the diagnostic categories for benign conditions
referred as suspected lung cancer. Infections represented the
largest increase in benign diagnoses. These cases were thought
appropriate to refer to secondary care in 56, 54 and 51% of patients
in years 1999–2000, 2000–2001 and 2001–2002, respectively. In
many other cases, however, it may have been appropriate on
medical grounds alone to expedite a diagnosis by urgent referral,
either because the condition required treatment or there was a
high probability that there might be cancer.
DISCUSSION
Introduction of the target ‘2-week wait’ scheme and DoH
guidelines on urgent referral of suspected lung cancer has so far
failed to achieve its primary objective of reducing waiting times.
The data generated by this paper suggest two linked explanations
for this unexpected finding: firstly, despite the publication of
national guidelines recommending urgent referral through the ‘2-
week wait’ scheme and local efforts to encourage this by
simplifying referral procedures with proforma-based faxed referral
letters/electronic referrals, a significant proportion of patients
continued to be referred by standard means. Only 57.5% of
patients were referred using the recommended ‘2-week wait’
scheme. 37.7% were referred urgently via conventional means.
Secondly, there has been an increase of 42% in the number of
urgent referrals for suspected lung cancer. This may reflect
increased awareness of the problem in primary care, the
perception of improved access to specialist teams or the
inflexibility resulting from specific guidelines. The latter is
suggested by the clear implication in some of the referral letters
of doubt about whether the patient should be seen by a specialist.
There may also have been a tendency to abuse the rapid access to
specialist advice, although most patients still fitted DoH criteria.
Table 4 Final diagnosis in all urgent referrals
Year
April 99– March 2000 April 2000– March 2001 April 2001– March 2002
Absolute % Absolute % Absolute %
Total referrals 286 100.0 352 100.0 404 100.0
All cancers 224 78.3 240 68.2 186 46.0
Primary lung cancers 202 70.6 212 60.2 164 40.6
NSCLC 161 56.3 173 49.1 131 32.4
SCLC 37 12.9 30 8.5 19 4.7
Mesothelioma 3 1.0 8 2.3 11 2.7
Carcinoid 1 0.3 1 0.3 3 0.7
Lymphoma 6 2.1 3 0.9 3 0.7
Metastatic 16 5.6 25 7.1 18 4.5
No cancer 62 21.7 112 31.8 218 54.0
NSCLC¼non-small-cell carcinoma; SCLC¼small-cell carcinoma.
Table 5 Stage of non-small-cell lung cancer
Stages
Year (s) 1 2 3 4
1999–2000 32 8 40 34
2000–2002 48 23 79 54
w
2¼2.51; P¼0.47.
Table 6 Benign diagnoses in patients referred urgently for suspected
lung cancer
Frequency
Condition 1999–2000 2000–2001 2001–2002
Conditions that can usually be managed in primary care
Infection 18 41 83
COPD 3 3 7
Goitre 3 1 0
Normal variant 1 1 9
ENT cause 1 3 5
CCF 1 2 2
Conditions usually managed by respiratory physicians (or complex)
Vascular markings 3 4 3
TB (old or active) 3 7 4
Benign lung tumour 1 0 5
Benign pleural shadows 5 6 17
Sarcoidosis 1 3 2
Benign lung shadow 5 0 15
Interstitial lung disease 4 19 9
Bronchiectasis 3 9 13
Other 0 4 13
DNA, died or refused tests 4 6 10
No diagnosis 6 3 21
Total 62 112 218
COPD¼chronic obstructive pulmonary disease; TB¼tuberculosis.
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proportion of referrals culminating in malignant diagnoses has
decreased from 78 to 46% in the 2 years since the guidelines were
implemented.
These linked observations (more referrals with lower proportion
of malignancy and a significant proportion of patients referred
outside the 2-week wait system) have two important consequences:
firstly that assessment of increasing numbers of patients with
benign disease will place further strain on the lung cancer services,
and secondly that the patients referred outside the 2-week wait will
be disadvantaged.
The first of these consequences is demonstrated in this paper by
the increase in median time to first clinic visit from 7 to 9 days
despite improvements in the efficiency of the referral process
(including the appointment of an additional consultant). The
second is illustrated by the finding that the waiting times were
longer for non-2-week wait referrals. The increased number of
referrals may have a beneficial influence on earlier diagnosis of
lung cancer, but this was not supported by the findings of this
study, as the stage did not change significantly. Moreover, making
an earlier diagnosis may improve survival but not necessarily
mortality – an effect of lead-time bias.
Thus, introduction of the guidelines and target wait scheme has
had a beneficial effect for those patients referred by the
recommended route, but a negative effect on those referred
urgently outside this system. Furthermore, waiting times reported
to the Government are based on patients referred through the
2-week wait system and thus Government figures on waiting times
for lung cancer do not reflect the true statistics. This may also
apply to other cancers. Although out-with the scope of this paper,
these data do prompt speculation that waiting times for urgent and
routine noncancer referrals seen by the same consultants might
also have increased as a consequence of the rapid increase in
suspected cancer patients referred since the introduction of the
guidelines.
The observed increase in early review of patients without cancer
does have beneficial effects. The reassurance provided by rapid
diagnosis and removal of a lengthy period of uncertainty is
important for the individual. Furthermore, the study showed that
over 50% of patients without cancer should probably have been in
a respiratory medicine clinic in any case irrespective of cancer
referral guidelines. Thus, the extra resources have had other
ancillary benefits.
Despite the benefits of seeing more patients quickly, if the
proposed Government targets of reducing the delay from referral
to treatment to no more than 2 months by December 2005 (NHS
Executive, 2000; National Institute for Clinical Excellence, 2005)
are to be achieved, it is important that accurate baseline statistics
are recorded. If the increase in referrals continues, considerable
further investment in cancer services will be required and referral
guidelines may need to be modified to reflect the management of
minor haemoptysis. Currently, NICE (NICE, 2005) recommend
offering the patient a chest radiograph prior to referral in patients
presenting with haemoptysis. So far, it cannot be recommended
that such patients are followed with a simple radiograph, but direct
access to CT scanning and possibly bronchoscopy could reduce the
burden on outpatient appointments while still identifying those
patients with benign disease who may need a respiratory
physician. Lastly, general practitioners should be aware that
not using the 2-week wait system gives inaccurate national
waiting time data and more importantly may disadvantage their
patients.
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